Yes. Fenofibrate tablets are permissible in hand luggage or checked baggage. Keep them in their original packaging with the prescription label visible to avoid delays at security checkpoints.
The UK Driving and Vehicle Licensing Agency (DVLA) does not require cholesterol values for licence renewal. However, if you are under a medical review, provide accurate lipid results to your doctor.
Common generic fenofibrate tablets are white, round or oval, and may be imprint-coded with the strength (e.g., “160” or “200”). Inactive ingredients can include lactose, magnesium stearate, and microcrystalline cellulose.
Formulation strength (160 mg vs 200 mg) and tablet size are generally similar, but excipients may vary. UK products must meet MHRA standards for quality and safety.
Fenofibrate is not a prohibited substance by the World Anti-Doping Agency (WADA). However, athletes should disclose all medications to their anti-doping authority to avoid inadvertent issues.
Fenofibrate was first synthesized in the 1970s as part of the fibrate family, aiming to develop agents that could lower triglycerides by activating PPAR-α. It received UK market approval in the early 1990s for severe hypertriglyceridaemia.
Generic fenofibrate is typically less expensive than patented statins or newer lipid therapies. Prices can vary between pharmacies, and the NHS provides it at standard prescription rates.
Take the missed tablet with your next main meal; the presence of dietary fat enhances absorption, so timing with a substantial meal is recommended.
It is best to keep fenofibrate in a cool, dry place away from humidity. A bathroom cabinet may become damp; storing the medication in a bedroom drawer or kitchen cupboard is preferable.
For lipid panels, fasting for 9-12 hours is traditionally recommended, though non-fasting tests are increasingly accepted. Fenofibrate does not require a specific fasting period beyond the laboratory’s protocol.
Fenofibrate belongs to the fibrate class of medicines and is used to improve abnormal blood-lipid levels. It is available in the United Kingdom as a prescription-only pill, most commonly in 160 mg and 200 mg strengths. The drug works by modifying the way the body processes fats, helping to lower triglycerides and raise “good” HDL-cholesterol while modestly reducing LDL-cholesterol. Fenofibrate is marketed under various generic names; no specific brand name is required for this educational article.
Fenofibrate activates a nuclear receptor called peroxisome proliferator-activated receptor-α (PPAR-α). By turning this receptor on, the drug stimulates enzymes that:
These actions together lower the amount of circulating triglycerides, modestly lower low-density lipoprotein (LDL) cholesterol, and raise HDL cholesterol. The therapeutic effect usually begins within a few days, reaches a steady level after 2-4 weeks, and persists as long as the medication is taken.
Fenofibrate is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for the following indications:
It is prescribed for adult patients (typically ≥ 18 years) who have documented lipid abnormalities that meet the above criteria.
Research studies have explored fenofibrate in several additional settings:
Disclaimer: Off-label use of fenofibrate requires careful medical assessment and monitoring. It should only be initiated by a qualified healthcare professional.
Regular monitoring helps ensure safety and effectiveness:
Promptly report any unexplained muscle symptoms, jaundice, or severe abdominal pain to a healthcare professional.
This article provides educational information about fenofibrate and is not a substitute for professional medical advice. Treatment decisions, including the use of fenofibrate for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
